RELATIONSHIP OF INSIGHT WITH MEDICATION ADHERENCE AND THE IMPACT ON OUTCOMES IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR DISORDER- RESULTS FROM A 1-YEAR EUROPEAN OUTPATIENT OBSERVATIONAL STUDY
Author(s)
Novick D1, Montgomery W2, Treuer T3, Aguado J4, Kraemer S5, Haro JM6
1Eli Lilly Holdings Limited, Windlesham, UK, 2Eli Lilly Australia, Sydney, Australia, 3Eli Lilly & Company, Budapest, Hungary, 4Parc Sanitari Sant Joan de Deu, CIBERSAM, Sant Boi de Llobregat, Spain, 5Eli Lilly and Company Ltd, Bad Homburg, Germany, 6Parc Sanitari Sant Joan de Déu, CIBERSAM, Universitat de Barcelona, Barcelona, Spain
OBJECTIVES Many patients with schizophrenia and bipolar disorder have impaired insight and low medication adherence. The aim of this post-hoc analysis is to explore the relationship between insight and medication adherence and their impact on the outcomes of patients with schizophrenia or bipolar disorder. METHODS We included 903 patients with schizophrenia or bipolar disorder who participated in an observational study conducted in Europe on the outcomes of patients treated with two oral formulations of olanzapine over a 1-year period. Evaluations included Clinical Global Impression (CGI), Global Assessment of Functioning (GAF), insight (Scale to Assess Unawareness of Mental Disorder, SUMD), non-adherence (Medication Adherence Rating Scale, MARS), and therapeutic alliance (Working Alliance Inventory, WAI). Correlations between variables were assessed by Spearman Correlation Coefficient (SCC). A path analysis was used to understand the relationship between insight, adherence, therapeutic alliance and outcomes. RESULTS
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PMH10
Topic
Clinical Outcomes
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Mental Health